GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Andembry® | CSL-312 | CSL312
garadacimab is an approved drug
Compound class:
Antibody
Comment: Garadacimab (CSL312) is a fully-human monoclonal antibody that inhibits activated factor XII (FXIIa) [4]. Peptide sequence alignments suggest that CSL312 may be the antibody referred to as VR115 in CSL Behring patent US9856325B2 [3]. Activation of FXII initiates the kallikrein-kinin cascade that drives hereditary angioedema (HAE) attacks. FXIIa also induces IL-6 and migration of fibroblasts in lung interstitium, promotes inflammation and represents a novel pathological pathway to fibrotic disease progression in idiopathic pulmonary fibrosis (IPF) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Garadacimab (CSL312) was progressed as a clinical candidate for the prophylactic treament of hereditary angioedema (i.e. to reduce frequency of attacks) [4] and idiopathic pulmonary fibrosis [2]. First approvals were issued by the regulatory agencies of the UK and Australia in January 2025 [1]. The EU's EMA authorised use of garadacimab the following month. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04656418 | CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks | Phase 3 Interventional | CSL Behring | 5 | |
| External links |
|
For extended ADME data see the following: European Medicines Agency (EMA) |
